search
Back to results

Sleep Disordered Breathing and Cardiopulmonary Disease in Peruvian Highlanders

Primary Purpose

Sleep Disordered Breathing, Sleep Apnea

Status
Completed
Phase
Not Applicable
Locations
Peru
Study Type
Interventional
Intervention
Inclined Sleep
Sponsored by
Johns Hopkins University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sleep Disordered Breathing

Eligibility Criteria

40 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion criteria

  • Age 40-80 years
  • Daytime oxyhemoglobin saturation ≥80%, seated.
  • Body mass index ≥25 kg/m2
  • Hemoglobin >13 g/dL in women and >15 g/dL in men
  • Ability to provide informed consent
  • Sleeps at home in same bed every night
  • Expected stable residence for at least 6 months
  • Sleeps with two pillows or fewer
  • Demonstrate acute improvement in SDB severity with postural therapy
  • Able to sleep ≥5 hours at an incline for all three nights during the run-in period

Exclusion criteria

  • Works the night-shift or a rotating shift
  • Has an indication or preference for sleeping upright, semi-recumbent or at an incline
  • Chronic insomnia or a non-respiratory sleep disorder
  • Physician-established diagnosis of diabetes, lung, cardiovascular, liver, or chronic kidney disease
  • Using home oxygen therapy or other respiratory assistive device [e.g., continuous positive airway pressure (CPAP), nebulizer]
  • Self-reported severe gastrointestinal reflux
  • Self-report of occult blood or history of gastrointestinal bleeding in the past 3 months
  • Pregnancy
  • Unable to sleep ≥5 hours at an incline for all three nights during the run-in period

The following exclusion criteria apply only for those undergoing spirometry for safety reasons. Participants with any one of these criteria, will be excluded from spirometry but can still participate in the rest of the screening phase:

  • Surgery of the heart, chest, lungs in the past 3 months (participants will be revisited at a later period)
  • Heart attack in the past 3 months (participants will be revisited at a later period)
  • History of eye surgery
  • History of abdominal surgery in the past 3 months.

Sites / Locations

  • Prisma Org

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Inclined Sleep

Flat Sleep

Arm Description

Inclined mattress at 15 degrees

Plane mattress

Outcomes

Primary Outcome Measures

Change in Respiratory Disturbance Index (RDI)
The investigators will measure a change in Respiratory Disturbance Index (RDI) defined as an oxygen desaturation of at least 4 percent associated with autonomic signs of arousal. Specifically, autonomic arousals are defined as concurrent rises in heart rate and attenuation of arterial tonometry. Normal < 5 percent 5 percent < Mild < 15 percent 15 percent < Moderate < 30 percent Severe > 30 percent
Change in Mean oxyhemoglobin saturation (percent) during sleep
The investigators will measure mean oxyhemoglobin saturation (%SaO2) during sleep as assessed by WatchPAT home sleep study at baseline and week 8.

Secondary Outcome Measures

Tolerability of postural therapy as assessed by adherence monitor
Adherence monitor will measure sleep over the set time points and tolerability is defined as a recorded time on the wedge for a minimum of 5 hours.
Change in average plasma hemoglobin concentration (g/dL)
Change in average Glycated hemoglobin test (HbA1c)
This will measure percentage (%) of HbA1c in the blood.
Change in serum erythropoietin (EPO) concentration
The concentration of EPO in the sample is expressed in International Units per litre (U/L) and is determined by calibration against a reference standard.
Change in soluble Vascular Endothelial Growth Factor (SVEGF-1) concentrations
Plasma levels of SVEGF-1 (pg/mL)
Change in homeostatic model assessment of insulin resistance (HOMA-IR)
Units of measurement is mass units.
Change in total plasma cholesterol level (mg/dL)
Change in plasma low-density lipoprotein (LDL) cholesterol level (mg/dL)
Change in plasma high-density lipoprotein (HDL) cholesterol level (mg/dL)
Change in plasma triglyceride concentration (mg/dL)
Change in Vascular endothelial growth factor receptor 1 (SVEGF-R1) concentration
Units of measurement pg/mL
Change in mean blood pressure (mmHg)
Change in Brachial Artery Reactivity Testing (BART) assessment
Assessed by endothelial function using high-frequency ultrasound visualized brachial artery reactivity testing. Endothelial function is characterized by flow-mediated vasodilation of the brachial artery, which is measured by comparing the brachial artery diameter at rest to the diameter after increased forearm blood flow (reactive hyperemia). Unit of measurement is mass units.

Full Information

First Posted
April 23, 2019
Last Updated
November 5, 2020
Sponsor
Johns Hopkins University
Collaborators
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
search

1. Study Identification

Unique Protocol Identification Number
NCT03927547
Brief Title
Sleep Disordered Breathing and Cardiopulmonary Disease in Peruvian Highlanders
Official Title
Sleep Disordered Breathing and Cardiopulmonary Disease in Peruvian Highlanders
Study Type
Interventional

2. Study Status

Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
September 29, 2019 (Actual)
Primary Completion Date
March 15, 2020 (Actual)
Study Completion Date
March 15, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Johns Hopkins University
Collaborators
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Overall objective: To understand the feasibility of performing a randomized trial using a simple, minimally-invasive postural therapy approach to improve sleep disordered breathing (SDB).
Detailed Description
Specific Aims: To examine the relative efficacy of postural therapy (a 15-degree wedge mattress) on measures of chronic cardiometabolic stress in high altitude residents. To determine the tolerability of postural therapy. Primary outcomes, at 4 and 8 weeks: Mean nocturnal oxyhemoglobin saturation (SPO2) Apnea-hypopnea index (AHI). Secondary outcomes Markers of hypoxemia exposure: the investigators will evaluate for differences in average hemoglobin and erythropoietin concentrations between intervention groups using t-tests or Wilcoxon rank sum tests, as considered appropriate. If transformations are necessary, the investigators will use Box-Cox power transform to identify the best transformation for the investigators' data. Markers of metabolic dysfunction: the investigators will evaluate for differences in average Glycated hemoglobin test (HbA1c), homeostatic model assessment of insulin resistance (HOMA-IR), total cholesterol, low-density lipoprotein cholesterol (LDL), High-density lipoprotein cholesterol (HDL), triglycerides, SVEGF-R1 , and soluble Vascular Endothelial Growth Factor (SVEGF-1) concentrations between intervention groups using t-tests or Wilcoxon rank sum tests, as appropriate. If transformations are necessary, the investigators will use Box-Cox power transform to identify the best transformation for the investigators' data. Markers of cardiometabolic stress: the investigators will evaluate for differences in average systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse, and % change in endothelial function (reactive hyperemia index) as assessed by brachial artery reactivity testing (BART) between intervention groups using t-tests or Wilcoxon rank sum tests, as considered appropriate. Adherence (the average number of nights during the 8-week period that participants slept on the wedge mattress),

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sleep Disordered Breathing, Sleep Apnea

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Masking Description
Subjects will undergo sleep study in subjects' randomized sleep posture. Randomization will be recorded separately from sleep study recordings. These recordings will be reviewed by trained sleep study technicians who will be blinded to randomization. Blood samples will also be assayed for markers of glucose control.
Allocation
Randomized
Enrollment
54 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Inclined Sleep
Arm Type
Experimental
Arm Description
Inclined mattress at 15 degrees
Arm Title
Flat Sleep
Arm Type
No Intervention
Arm Description
Plane mattress
Intervention Type
Device
Intervention Name(s)
Inclined Sleep
Other Intervention Name(s)
wedge mattress, postural therapy
Intervention Description
Study participants randomized to the interventional arm will be instructed to sleep on inclined wedge mattress.
Primary Outcome Measure Information:
Title
Change in Respiratory Disturbance Index (RDI)
Description
The investigators will measure a change in Respiratory Disturbance Index (RDI) defined as an oxygen desaturation of at least 4 percent associated with autonomic signs of arousal. Specifically, autonomic arousals are defined as concurrent rises in heart rate and attenuation of arterial tonometry. Normal < 5 percent 5 percent < Mild < 15 percent 15 percent < Moderate < 30 percent Severe > 30 percent
Time Frame
Baseline, 4 weeks, 8 weeks
Title
Change in Mean oxyhemoglobin saturation (percent) during sleep
Description
The investigators will measure mean oxyhemoglobin saturation (%SaO2) during sleep as assessed by WatchPAT home sleep study at baseline and week 8.
Time Frame
Baseline, 4 weeks, 8 weeks
Secondary Outcome Measure Information:
Title
Tolerability of postural therapy as assessed by adherence monitor
Description
Adherence monitor will measure sleep over the set time points and tolerability is defined as a recorded time on the wedge for a minimum of 5 hours.
Time Frame
2, 4, 6 and 8 weeks
Title
Change in average plasma hemoglobin concentration (g/dL)
Time Frame
Baseline, 8 weeks
Title
Change in average Glycated hemoglobin test (HbA1c)
Description
This will measure percentage (%) of HbA1c in the blood.
Time Frame
Baseline, 8 weeks
Title
Change in serum erythropoietin (EPO) concentration
Description
The concentration of EPO in the sample is expressed in International Units per litre (U/L) and is determined by calibration against a reference standard.
Time Frame
Baseline, 8 weeks
Title
Change in soluble Vascular Endothelial Growth Factor (SVEGF-1) concentrations
Description
Plasma levels of SVEGF-1 (pg/mL)
Time Frame
Baseline, 8 weeks
Title
Change in homeostatic model assessment of insulin resistance (HOMA-IR)
Description
Units of measurement is mass units.
Time Frame
Baseline, 8 weeks
Title
Change in total plasma cholesterol level (mg/dL)
Time Frame
Baseline, 8 weeks
Title
Change in plasma low-density lipoprotein (LDL) cholesterol level (mg/dL)
Time Frame
Baseline, 8 weeks
Title
Change in plasma high-density lipoprotein (HDL) cholesterol level (mg/dL)
Time Frame
Baseline, 8 weeks
Title
Change in plasma triglyceride concentration (mg/dL)
Time Frame
Baseline, 8 weeks
Title
Change in Vascular endothelial growth factor receptor 1 (SVEGF-R1) concentration
Description
Units of measurement pg/mL
Time Frame
Baseline, 8 weeks
Title
Change in mean blood pressure (mmHg)
Time Frame
Baseline, 8 weeks
Title
Change in Brachial Artery Reactivity Testing (BART) assessment
Description
Assessed by endothelial function using high-frequency ultrasound visualized brachial artery reactivity testing. Endothelial function is characterized by flow-mediated vasodilation of the brachial artery, which is measured by comparing the brachial artery diameter at rest to the diameter after increased forearm blood flow (reactive hyperemia). Unit of measurement is mass units.
Time Frame
Baseline, 8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria Age 40-80 years Daytime oxyhemoglobin saturation ≥80%, seated. Body mass index ≥25 kg/m2 Hemoglobin >13 g/dL in women and >15 g/dL in men Ability to provide informed consent Sleeps at home in same bed every night Expected stable residence for at least 6 months Sleeps with two pillows or fewer Demonstrate acute improvement in SDB severity with postural therapy Able to sleep ≥5 hours at an incline for all three nights during the run-in period Exclusion criteria Works the night-shift or a rotating shift Has an indication or preference for sleeping upright, semi-recumbent or at an incline Chronic insomnia or a non-respiratory sleep disorder Physician-established diagnosis of diabetes, lung, cardiovascular, liver, or chronic kidney disease Using home oxygen therapy or other respiratory assistive device [e.g., continuous positive airway pressure (CPAP), nebulizer] Self-reported severe gastrointestinal reflux Self-report of occult blood or history of gastrointestinal bleeding in the past 3 months Pregnancy Unable to sleep ≥5 hours at an incline for all three nights during the run-in period The following exclusion criteria apply only for those undergoing spirometry for safety reasons. Participants with any one of these criteria, will be excluded from spirometry but can still participate in the rest of the screening phase: Surgery of the heart, chest, lungs in the past 3 months (participants will be revisited at a later period) Heart attack in the past 3 months (participants will be revisited at a later period) History of eye surgery History of abdominal surgery in the past 3 months.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
William Checkley
Organizational Affiliation
Johns Hopkins University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Prisma Org
City
Puno
Country
Peru

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Sleep Disordered Breathing and Cardiopulmonary Disease in Peruvian Highlanders

We'll reach out to this number within 24 hrs